Prostate cancers initially need the male hormone testosterone for growth. Hormone therapies that lower the level of testosterone are among the most effective treatments for prostate cancers that have spread to other organs (metastasized). The benefits of hormone treatments do not last, however. Over time, many prostate cancers continue to grow despite hormonal therapies (and are called “castration-resistant” prostate cancer).
Docetaxel is the chemotherapy drug most often give to men who develop castration-resistant prostate cancer, but often the cancer continues growing despite this drug. BIND-014 is an investigational drug made of tiny particles of docetaxel that may increase the amount of docetaxel that gets into tumor cells.
The purpose of this study is to evaluate the safety and effectiveness of BIND-014 in men with castration-resistant prostate cancer. BIND-014 is given intravenously (by vein).